Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?
Author:
Publisher
Elsevier BV
Subject
Clinical Biochemistry,Oncology
Reference17 articles.
1. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work;de Lima;Blood,1997
2. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia;Estey;Blood,1996
3. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse;Giles;Blood,2009
4. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse;Levis;Blood,2011
5. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial;Faderl;J Clin Oncol,2012
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. FLAG-Ida’ya Karşı FLAG-Dauno: Relaps/Refrakter Akut Lösemi Olgularında Bursa Uludağ Üniversitesi Deneyimi;Uludağ Üniversitesi Tıp Fakültesi Dergisi;2024-05-17
2. Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study;Annals of Hematology;2023-09-08
3. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience;Hematology;2023-05-16
4. OLFML2A Overexpression Predicts an Unfavorable Prognosis in Patients with AML;Journal of Oncology;2023-02-22
5. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response;Blood Cancer Journal;2022-01-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3